QED Pharmaceutical Services’ License For SAS Clinical Data Integration

• Email
• Print
• ( 0 )
• 

To cultivate new business dimensions while strengthening the existing relationship, Business Analytics Software and Services leader, SAS has obtained license for its SAS Clinical Data Integration from QED Pharmaceutical Services.

To cultivate new business dimensions while strengthening the existing relationship, Business Analytics Software and Services leader, SAS has obtained license for its SAS Clinical Data Integration from QED Pharmaceutical Services. This license will facilitate its drug development clients to easily form partnerships with key biopharmaceutical companies.

Expressing his views said Dr. Ramana Kuchibhatla, QED founder said, The availability of SAS Clinical Data Integration has made it possible for QED to efficiently implement complex data standards such as the CDISC standards. This allows us to help our clients - predominantly small and sometimes virtual biopharmaceutical companies - achieve important milestones despite their size. Compliance with the latest CDISC standards makes growing drug developers like our clients very attractive partners to large pharma companies that are looking to in-license successful drug development programs. The overall value created by SAS Clinic

al Data Integration to both QED as a service company and our clients by making them attractive partners and ensuring regulatory compliance is tremendous.

He further mentioned, Its as if we have designed an efficient mechanical engine, and now, with little modification for each clinical trial, we can crank out CDISC-compliant data and get our clients datasets output in regulatory submission-ready formats.

Both the companies are enjoying this win-win deal as QED, a global contract research organization (CRO) with offices in India and the United States, will continue its strong market momentum for SAS Clinical Data Integration. Whereas SAS is enjoying by offering a comprehensive portfolio of life sciences software solutions for pharmaceutical, biotechnology and medical device companies.

According to Sudipta K Sen, Regional Director South-East Asia, CEO & MD SAS India, We are happy to be associated with QED pharmaceutical. The new deployme